Search research articles
Contact Us
Filters
Showing results (101-110 of 136) with videos related to
Page
of 14
Sort By:
The American Journal of Tropical Medicine and Hygiene
|
September 19, 2022
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease
Douglas M Watts, Jonna L B Westover, Pedro M Palermo, et al.
Vaccine
|
June 28, 2016
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains
Richard C Condit, Anna-Lise Williamson, Rebecca Sheets, et al.
Vaccine
|
March 30, 2010
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity
Thomas P Monath, Cynthia K Lee, Justin G Julander, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports
|
November 20, 2002
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002
Martin S Cetron, Anthony A Marfin, Kathleen G Julian, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 18, 2006
A live, attenuated recombinant West Nile virus vaccine
Thomas P Monath, Jian Liu, Niranjan Kanesa-Thasan, et al.
Vaccine: X
|
April 28, 2020
Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile
Thomas P Monath, Jeroen Kortekaas, Douglas M Watts, et al.
Vaccine: X
|
August 7, 2019
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
Thomas P Monath, Patricia E Fast, Kayvon Modjarrad, et al.
Viruses
|
March 27, 2025
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model
Amy C Shurtleff, John C Trefry, Sheri Dubey, et al.
Vaccine
|
September 11, 2019
Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases
Marcia A Blackman, Mark A Marchionni, John Gilly, et al.
Vaccine
|
August 18, 2006
Viral vectors for malaria vaccine development
Shengqiang Li, Emily Locke, Joseph Bruder, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 136) with videos related to
Sort By:
Page
of 14
The American Journal of Tropical Medicine and Hygiene
|
September 19, 2022
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease
Douglas M Watts, Jonna L B Westover, Pedro M Palermo, et al.
Vaccine
|
June 28, 2016
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains
Richard C Condit, Anna-Lise Williamson, Rebecca Sheets, et al.
Vaccine
|
March 30, 2010
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity
Thomas P Monath, Cynthia K Lee, Justin G Julander, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports
|
November 20, 2002
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002
Martin S Cetron, Anthony A Marfin, Kathleen G Julian, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 18, 2006
A live, attenuated recombinant West Nile virus vaccine
Thomas P Monath, Jian Liu, Niranjan Kanesa-Thasan, et al.
Vaccine: X
|
April 28, 2020
Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile
Thomas P Monath, Jeroen Kortekaas, Douglas M Watts, et al.
Vaccine: X
|
August 7, 2019
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
Thomas P Monath, Patricia E Fast, Kayvon Modjarrad, et al.
Viruses
|
March 27, 2025
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model
Amy C Shurtleff, John C Trefry, Sheri Dubey, et al.
Vaccine
|
September 11, 2019
Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases
Marcia A Blackman, Mark A Marchionni, John Gilly, et al.
Vaccine
|
August 18, 2006
Viral vectors for malaria vaccine development
Shengqiang Li, Emily Locke, Joseph Bruder, et al.
Page
of 14